Stanniocalcin-1 as a Novel Marker to Detect Minimal Residual Disease of Human Leukemia

この論文にアクセスする

この論文をさがす

著者

    • TOHMIYA YASUO
    • Department of Rheumatology and Hematology, Tohoku University Graduate School of Medicine
    • KOIDE YOSHIO
    • Department of Molecular Diagnostics, Tohoku University Graduate School of Medicine
    • FUJIMAKI SHINICHI
    • Department of Molecular Diagnostics, Tohoku University Graduate School of Medicine
    • HARIGAE HIDEO
    • Department of Molecular Diagnostics, Tohoku University Graduate School of Medicine
    • FUNATO TADAO
    • Department of Molecular Diagnostics, Tohoku University Graduate School of Medicine
    • KAKU MITSUO
    • Department of Molecular Diagnostics, Tohoku University Graduate School of Medicine
    • ISHII TOMONORI
    • Department of Rheumatology and Hematology, Tohoku University Graduate School of Medicine
    • MUNAKATA YASUHIKO
    • Department of Rheumatology and Hematology, Tohoku University Graduate School of Medicine
    • KAMEOKA JUNICHI
    • Department of Rheumatology and Hematology, Tohoku University Graduate School of Medicine
    • SASAKI TAKESHI
    • Department of Rheumatology and Hematology, Tohoku University Graduate School of Medicine

抄録

Stanniocalcin is a glycoprotein hormone that regulates the calcium level in fish. We found that mRNA of human stanniocalcin 1 (STC-1) is detectable in phytohemagglutinin-stimulated T cells and in most human leukemia cell lines, suggesting a role of STC-1 for cell proliferation. This finding prompts us to study the usefulness of STC-1 for monitoring acute leukemia. The levels of STC-1 transcripts increased in patients with acute leukemia at diagnosis and relapse, as judged by quantitative real-time RT-PCR. Levels of transcripts rapidly decreased to within the cut-off levels, when the blast numbers decreased with chemotherapy. Prolonged elevation of STC-1 levels after treatment was associated with a poor prognosis. All of 7 patients relapsed 1 to 4 months after they showed an elevated level of the transcripts in clinical remission. These results indicate that STC-1 is a novel marker for minimal residual disease of acute leukemia, and for an early diagnosis of relapse.

収録刊行物

  • THE TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE

    THE TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE 204(2), 125-133, 2004-10-01

    東北ジャーナル刊行会

参考文献:  22件中 1-22件 を表示

被引用文献:  2件中 1-2件 を表示

各種コード

  • NII論文ID(NAID)
    10013562947
  • NII書誌ID(NCID)
    AA00863920
  • 本文言語コード
    ENG
  • 資料種別
    ART
  • ISSN
    00408727
  • データ提供元
    CJP書誌  CJP引用  J-STAGE 
ページトップへ